Press | Thyme Care

Thyme Care and Texas Oncology reduce cost of care for a leading cancer drug through weight-based dosing of Keytruda

Written by Cancer Letter | Nov 18, 2026, 5:40:12 PM

Thyme Care and Texas Oncology announced data showing that weight-based dosing of pembrolizumab (Keytruda), delivered under a value-based care agreement, meaningfully reduced cost of care for their shared Medicare Advantage population.

Read full article here.